[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595351":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":29,"locations":39,"responsibleParty":91,"collaborators":93,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":17,"eligibilityCriteria":103,"healthyVolunteers":100,"sex":104,"minAge":105,"maxAge":20,"enrollmentInfo":106,"targetDuration":20,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":75,"whyStopped":20,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Boston Children's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participation","EXPERIMENTAL","Participants eligible to enroll will be provided with the OnTrackCF app (intervention), and will use the app for 4-12 weeks before completing feasibility measures and a qualitative interview.",[13],"Behavioral: OnTrackCF",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","OnTrackCF","OnTrackCF is a mHealth application co-developed with Upstream Dream. It is designed specifically to track and support adherence to CFTR modulator therapy. The app allows users to track their modulator intake and disease symptoms while supporting their adherence goals using Behavioral Change Techniques (BCTs) with empirical evidence of efficacy. The BCTs are administered primarily in the form of messages designed to deliver specific BCTs. The app sends up to 3 adherence support messages per day and provides detailed data to the user about their adherence levels, adherence goals, and disease symptoms. This process will continue until we reach an N=60 AWCF enrolled OR demonstrate that we have achieved 12 weeks of sustained user engagement with the app.",[9],null,[22,26],{"name":23,"affiliation":24,"role":25},"Kristin Riekert, PhD","Johns Hopkins University","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":28,"role":25},"Gabriela Oates, PhD","University of Alabama at Birmingham",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":20,"email":34},"Emma M McWilliams, BA","CONTACT","617-355-7534","emma.mcwilliams@childrens.harvard.edu",{"name":36,"role":32,"phone":37,"phoneExt":20,"email":38},"Callie Bacon, MPH","617-919-7696","callie.bacon@childrens.harvard.edu",[40,59,74],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"University of Alabama-Birmingham","NOT_YET_RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-86.80249,33.52066,{"lat":52,"lon":51},[55,58],{"name":27,"role":32,"phone":56,"phoneExt":20,"email":57},"(205) 996-5689","goates@uabmc.edu",{"name":27,"role":25,"phone":20,"phoneExt":20,"email":20},{"facility":24,"status":42,"city":60,"state":61,"zip":62,"country":46,"countryCode":47,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Baltimore","Maryland","21218",{"type":49,"coordinates":64},[65,66],-76.61219,39.29038,{"lat":66,"lon":65},[69,73],{"name":70,"role":32,"phone":71,"phoneExt":20,"email":72},"Kristin A. Riekert, PhD","443-286-9313","kriekert@jhmi.edu",{"name":70,"role":25,"phone":20,"phoneExt":20,"email":20},{"facility":5,"status":75,"city":76,"state":77,"zip":78,"country":46,"countryCode":47,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"RECRUITING","Boston","Massachusetts","02115",{"type":49,"coordinates":80},[81,82],-71.05977,42.35843,{"lat":82,"lon":81},[85,89],{"name":86,"role":32,"phone":87,"phoneExt":20,"email":88},"Gregory Sawicki","617-355-1900","gregory.sawicki@childrens.harvard.edu",{"name":90,"role":25,"phone":20,"phoneExt":20,"email":20},"Gregory Sawicki, MD, MPH",{"type":25,"investigatorFullName":86,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Co-Chair of the Success with Therapies Research Consortium",[94,96,97],{"name":95,"class":6},"Cystic Fibrosis Foundation",{"name":24,"class":6},{"name":28,"class":6},"100595351","ontrackcf-engagement-feasibility-and-acceptability-study-100595351",false,"NCT07031323","OnTrackCF: Engagement, Feasibility, and Acceptability Study","Inclusion Criteria:\n\n1. Diagnosed with CF\n2. 18+ years of age\n3. Prescribed a CFTR modulator therapy to be taken twice a day\n4. Can speak and read English\n5. Have regular access to an iOS or Android tablet or smartphone with internet access.\n\nExclusion Criteria:\n\n1\\) Any situation, in the opinion of the Investigator, that would compromise the safety of the patient or the quality of the data","ALL","18 Years",{"count":107,"type":108},60,"ESTIMATED","INTERVENTIONAL",[111],"NA","This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF).",[114,115],"Cystic Fibrosis (CF)","Cystic Fibrosis - Complete",[117,118,119,120,121,122],"adherence","mHealth","mobile health","digital health","medication adherence","CFTR Modulators","2025-12-01",{"date":125,"type":126},"2025-12-05","ACTUAL",{"date":128,"type":126},"2025-11-20",{"date":130,"type":108},"2026-12",{"name":5,"class":6},3]